The phase I clinical trial CHRYSALIS evaluated the combination of lazertinib (a third-generation EGFR TKI) and amivantamab (a bi-specific antibody that targets both MET and EGFR) in patients with osimertinib-relapsed and chemotherapy-naïve advanced NSCLC [32,96]. Here, MET is linked to non-small cell lung carcinoma.